Vischer advised Mosanna Therapeutics in connection with its USD 80m Series A funding round. Headquartered in Basel, Switzerland, the clinical-stage biotech company, is working on a nighttime nasal spray to treat obstructive sleep apnea (OSA).
Tags :Matthias Staehelin
Vischer advised the co-lead and other new investors in Aktiia’s oversubscribed USD 42m Series-B funding-round. Pursuant to the transaction, the blood pressure intelligence platform reached a total funding of USD 100m to date. The
Vischer advised GlycoEra in connection with its financing round. The Swiss biotechnology company, closed a USD 130 million Series B funding. BGPartner advised the lead investor Novo Holdings and new investor LifeArc Ventures on all Swiss
Vischer advised Chinese companies Kelun-Biotech and Harbour BioMed in all Swiss law matters of a licencing agreement. Moreover, the Swiss law firm assisted RTW, an investor, within the seed financing round of Winward Bio, the
Vischer advised Ikerian, a healthcare software platform company, on its first round of USD 8m Series B financing to advance its AI platform. The Series B financing round is led by strategic investor Sanoptis led
Vischer advised Mininavident, located in Liestal, a developer and manufacturer of the world’s smallest dynamic navigation system for dental implant placement, which was acquired by the Straumann Group, a global leader in tooth replacement,
Oculis Holding has completed a financing of approximately $59m, consisting of the issuance of 5,000,000 of its ordinary shares at a purchase price of $11.75 per share. A prospectus required for the listing on the Nasdaq Iceland
The Swiss dental startup Odne has raised USD 5.5m to fund the upcoming US market launch for their minimal invasive Root Preservation Technology (RPT). The Series A1 round for Odne, was led by Revere Partners (
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional investment by Bristol Meyer Squibb (BMS) to further support the development of its innovative platform to enable high-throughput design
Proteomedix, a Swiss private, commercial-stage diagnostics oncology company and Water Biotech are forming together a company called Onconetix. The transaction is implemented by the acquisition of Proteomedix for an all stock consideration. Onconetix’s commercial
